Stanley Capital Partners exits Irish speciality pharma firm Noden Pharma with 6.7x return

Stanley Capital Partners has exited its portfolio company Noden Pharma DAC (Noden Pharma) to a European business in the specialist pharmaceutical sector.

SCP exits the business having achieved a COC of 6.7x and an IRR of 151%. The sale of Noden Pharma marks the first exit since SCP was formed.

Headquartered in Dublin, Noden Pharma is a global speciality pharmaceutical company focused on the manufacturing of prescription medicines across a variety of cardiovascular treatments for patients who are intolerant to mainstream treatments.

SCP Founding Partner, Simon Cottle, said “We used our research to both originate Noden and create value in the business enabling them to transform the business from a subsidiary into a successful ongoing platform which resulted in a successful exit through our joint efforts in transforming the business.”

Get the week’s top news delivered directly to your inbox – Sign up for our newsletter

Patrick Hargutt, SCP Founding Partner, said: “We’re proud to have supported the growth of Noden Pharma and its team globally.”

Stanley Capital Partners LLP (SCP) is a fast-growing European-focused mid-market private equity firm using research and technology to identify investment opportunities to transform businesses in the growth sectors of Healthcare, Technology and Resource Efficiency.

SCP targets businesses with enterprise values of $250m-2.5bn or more where SCP can partner with management teams to create value through M&A, operational change, and technology enablement.

SCP was founded in 2019 by Simon Cottle, James Brooks and Patrick Hargutt and has a team of 12 professionals. SCP has led four investments since its formation in 2019, evidencing SCP’s strong ability to originate investment opportunities and deploy capital. SCP has assets under management of over $440m today.

Source: Press Release

Can’t stop reading? Read more